BPC157/TB-500 BLEND (10mg)

Manufactured in the USA by a Licensed Pharmaceutical Facility
Veteran Operated Company

The BPC-157 / TB-500 peptide blend is a research-driven combination designed to support studies examining synergistic regenerative signaling mechanisms. BPC-157, a pentadecapeptide known for its involvement in angiogenic and fibroblast-related pathways, is paired with TB-500, a thymosin beta-4–derived fragment commonly used in research involving actin regulation, cellular mobility, and tissue-modeling dynamics. Together, these peptides are frequently studied for their coordinated influence on wound-repair models, inflammatory-pathway responses, and structural tissue behavior in controlled laboratory environments.

Researchers often use this blend to evaluate multi-pathway regenerative interactions, including angiogenesis signaling, cytoskeletal modulation, and extracellular matrix remodeling. The combination allows scientists to explore broader mechanistic interactions than either peptide offers individually, making it a preferred formulation for complex regeneration and repair-model research.

Each batch of Nova9 BPC-157 / TB-500 is produced in a licensed U.S. pharmaceutical manufacturing facility and verified at ≥99% purity, ensuring reproducibility, structural integrity, and consistent performance across advanced peptide studies. Supplied as a lyophilized powder, it is optimized for controlled laboratory environments requiring high-precision peptide formulations.

Made in the USA by a Licensed Pharmaceutical Facility
Veteran Operated Company

For Research Use Only. Not for human consumption, not for veterinary use, and not for diagnostic or therapeutic purposes. All customers certify these materials will be used solely in controlled laboratory environments.